Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Ethnopharmacol ; 302(Pt A): 115700, 2023 Feb 10.
Artículo en Inglés | MEDLINE | ID: mdl-36126782

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: Obesity is a critical threat to global health, and brown adipose tissue (BAT) is a potential target for the treatment of obesity and comorbidities. Xuezhikang Capsule (XZK), an extract of red yeast rice, has remarkable clinical efficacy and is widely used for the treatment of hyperlipidemia and coronary heart disease. However, its modulatory effect on BAT remains unknown. AIM OF THIS STUDY: The aim of this study was to investigate the protective mechanism of XZK in the obese spontaneously hypertensive rat (SHR) model by evaluating the regulatory effect of XZK on the BAT gene profile through transcriptome sequencing. MATERIALS AND METHODS: The SHRs were randomly divided into four groups: the standard chow diet (STD) group, the STD supplemented with 126 mg/kg of XZK group, the high-fat diet (HFD) group, and the HFD supplemented with 126 mg/kg of XZK group. All SHRs were fed for 18 weeks. The metabolic phenotypes, including body weight, fat mass, oral glucose tolerance test (OGTT), and serum glucose and lipid levels, was evaluated, and hematoxylin and eosin staining (H&E) staining was performed to evaluate the adipose tissue histopathological phenotype. Transcriptome sequencing was performed to determine the mechanism by which XZK improves the metabolic phenotype and the expression of key differential expression genes was verified by real-time quantitative polymerase chain reaction (qRT-PCR). RESULTS: XZK inhibited HFD-induced weight gain and adipose tissue remodeling in SHRs and prevented hypertrophy of epididymal adipocytes and maintained the brown fat phenotype. XZK intervention also improved glucose and lipid metabolism in SHRs, as suggested by a reduction in serum triglyceride (TG), low-density cholesterol (LDL-C), and fasting blood glucose (FBG) levels as well as increasing in serum high-density cholesterol (HDL-C) levels. Transcriptome sequencing analysis confirmed the regulatory effect of XZK on the gene expression profile of BAT, and the expression patterns of 45 genes were reversed by the XZK intervention. Additionally, the results of the transcriptome analysis of 10 genes that are important for brown fat function were in line with the results of qRT-PCR. CONCLUSIONS: XZK protected SHRs from HFD-induced obesity, inhibited fat accumulation and improved glucolipid metabolism. Additionally, the protective effect of XZK on the overall metabolism of obese SHRs might partly be related to its regulatory effect on the BAT gene expression profile. These findings might provide novel therapeutic strategies for obesity-related metabolic diseases in traditional Chinese medicine (TCM).


Asunto(s)
Medicamentos Herbarios Chinos , Obesidad , Animales , Ratas , Tejido Adiposo Pardo/efectos de los fármacos , Tejido Adiposo Pardo/metabolismo , Colesterol , Dieta Alta en Grasa , Glucosa , Enfermedades Metabólicas/prevención & control , Ratones Endogámicos C57BL , Obesidad/complicaciones , Obesidad/tratamiento farmacológico , Obesidad/metabolismo , Ratas Endogámicas SHR , Transcriptoma , Medicamentos Herbarios Chinos/farmacología , Modelos Animales de Enfermedad , Humanos , Ratones
2.
Medicine (Baltimore) ; 101(28): e29507, 2022 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-35839043

RESUMEN

OBJECTIVE: The association of low 25-hydroxyvitamin D level with mortality and rehospitalization remains inconsistent in patients with heart failure. This systematic review and meta-analysis aimed to evaluate the value of blood 25-hydroxyvitamin D level in predicting all-cause mortality and hospitalization in heart failure patients. METHODS: Two reviewers independently search the articles indexed in PubMed and Embase databases until November 30, 2021. Only the prospective or retrospective cohort studies evaluating the association of blood 25-hydroxyvitamin D level with all-cause mortality and rehospitalization in heart failure patients were selected. The predictive value of 25-hydroxyvitamin D level was summarized by pooling multivariable adjusted risk estimates for the bottom versus reference top 25-hydroxyvitamin D level. RESULTS: Seven studies with a total of 5941 patients with heart failure were identified. The pooled adjusted risk ratio (RR) of all-cause mortality was 1.37 (95% confidence interval [CI] 1.13-1.66), with significant heterogeneity (I2 = 70.5%; P = 0.002). However, there was no clear association between low 25-hydroxyvitamin D level and all-cause rehospitalization risk (RR 1.38; 95% CI 0.87-2.19). CONCLUSIONS: Low blood level of 25-hydroxyvitamin D may be an independent risk factor for all-cause mortality in patients with heart failure. Serum 25-hydroxyvitamin D level may provide prognostic information in heart failure patients. Additional randomized controlled trials are required to explore whether treatment of 25-hydroxyvitamin D deficiency by supplementation of vitamin D can improve survival in heart failure patients.


Asunto(s)
Insuficiencia Cardíaca , Deficiencia de Vitamina D , Calcifediol , Insuficiencia Cardíaca/complicaciones , Humanos , Estudios Prospectivos , Estudios Retrospectivos , Factores de Riesgo , Vitamina D
3.
Carbohydr Polym ; 146: 52-7, 2016 08 01.
Artículo en Inglés | MEDLINE | ID: mdl-27112850

RESUMEN

To improve the aqueous solubility of the anticancer agent paclitaxel (PTX), a newly conformed bipolymer paclitaxel-nanoparticle using tea polysaccharide (TPS) and zein was prepared and characterized. Tea polysaccharide was used as a biopolymer shell and zein was as the core and the optimal formula was subjected to the characteristic study by TEM, DSC, FTIR and in vitro release study. Results showed that the optimal particle was acquired with particle yield at 40.01%, drug loading at 0.12% and diameters around 165nm when the concentration of tea polysaccharide was set at 0.2%, and the amount of PTX:zein=1:10. The particle was a nanoparticle with spherical surface and the encapsulated PTX was in an amorphous form rather than cystalline form. PTX was interacted with zein and polysaccharide through O H and CO groups and it had a sustained release. The results suggested that the novel bipolymer might be a promising agent for PTX delivery and tea polysaccharide was demonstrated its function in drug delivery system.


Asunto(s)
Nanopartículas/química , Paclitaxel/química , Polímeros/química , Polisacáridos/química , Portadores de Fármacos/química , Tamaño de la Partícula , Polímeros/síntesis química , Té/química , Zeína/química
4.
Artículo en Inglés | MEDLINE | ID: mdl-26698235

RESUMEN

Total flavonoid tablet from Anemarrhenae Rhizoma (Zhimu tablet), which was made of total polyphenol components extracted from the dried rhizome of Anemarrhena asphodeloides Bge. (Zhimu in Chinese), is a novel traditional Chinese medicine prescribed for the treatment of diabetes. Mangiferin (MF) and neomangiferin (NMF) are the two main components detected and determined in Zhimu tablet, accounting for 8.9% of the total weight of each tablet. In the present study, high performance liquid chromatography (HPLC) coupled with time-of-flight (TOF) tandem mass spectrometry (MS) was applied to characterize the metabolites of MF and NMF in rat plasmas collected at different time points after oral administration of Zhimu tablet at a dose of 3.63g/kg (corresponding to 270mg/kg MF). Accurate mass measurement was used to determine the elemental composition of metabolites and thus to confirm the proposed structures of identified metabolites. Time points of appearance of some metabolites, such as isomers, were also taken into account during the structure confirmation. A total of 21 potential metabolites were found in rat plasma at different time points, and the metabolic pathways in vivo were involved in hydrolysis, methylation, glucuronide conjugation, glycoside conjugation, sulphation, dehydration and isomerisation. Furthermore, a selective and accurate LC-MS assay method was developed and validated for the quantification of MF in plasma. Semi-quantification of main conjugated metabolites was also performed in order to describe the dynamic metabolism profiles of polyphenol components in Zhimu tablet. MF concentration in plasma reached 1.36±0.47µgmL(-1) about 5.0h after oral administration of Zhimu tablet, which showed a 3.24- and 4.91-fold increase in plasma maximum concentration and area under the concentration-time curve (AUC) from 0 to 24h of MF compared with those for rats administered with free MF, respectively. The results indicated that the pharmacokinetic processes and bioavailability of MF in rats would be affected by other components in Zhimu tablet.


Asunto(s)
Anemarrhena/química , Polifenoles/sangre , Comprimidos , Administración Oral , Animales , Cromatografía Líquida de Alta Presión , Espectrometría de Masas , Polifenoles/administración & dosificación , Ratas , Estándares de Referencia , Reproducibilidad de los Resultados
5.
Int J Biol Macromol ; 81: 967-74, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26410811

RESUMEN

In order to investigate the hypoglycemic effects and potential mechanism of tea polysaccharides (TPS) on diabetes, type 2 diabetes mellitus (T2DM) mice were established and treated with TPS. Results showed that TPS treatment could result in the increase of body weight and the decrease of blood glucose in the diabetic mice. The contents of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) were decreased significantly (p<0.05) while the contents of triglyceride (TG) and (high-density lipoprotein cholesterol) HDL-c were almost restored to the normal levels. TPS possessed the efficacy of insulin resistance alleviation and exerted obvious cytoprotective action. The enzyme activities of superoxide dismutase (SOD) and glutathione peroxidase (GPX) were notably improved in both liver and kidney tissues (p<0.05) after the treatment of TPS. Furthermore, the expressions of PI3Kp85/p-Akt/GLUT4 were upregulated by TPS, which indicated the involvement of the PI3K/Akt signal pathway in the hypoglycemic mechanism of TPS. Results suggested that TPS could ameliorate the T2MD and might be a promising candidate functional food or medicine for T2DM treatment.


Asunto(s)
Diabetes Mellitus Experimental/tratamiento farmacológico , Hipoglucemiantes/farmacología , Fosfatidilinositol 3-Quinasas/metabolismo , Polisacáridos/uso terapéutico , Proteínas Proto-Oncogénicas c-akt/metabolismo , Transducción de Señal/efectos de los fármacos , Té/química , Animales , Glucemia/metabolismo , Western Blotting , Peso Corporal/efectos de los fármacos , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/patología , Prueba de Tolerancia a la Glucosa , Transportador de Glucosa de Tipo 4/metabolismo , Insulina/sangre , Riñón/efectos de los fármacos , Riñón/enzimología , Lípidos/sangre , Hígado/efectos de los fármacos , Hígado/enzimología , Masculino , Ratones , Polisacáridos/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA